高级检索
邢续扬, 王孝春, 何伟. 肿瘤免疫治疗及其药物研发进展[J]. 中国药科大学学报, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
引用本文: 邢续扬, 王孝春, 何伟. 肿瘤免疫治疗及其药物研发进展[J]. 中国药科大学学报, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
Citation: XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102

肿瘤免疫治疗及其药物研发进展

Advances in research on tumor immunotherapy and its drug development

  • 摘要: 分子生物学和肿瘤生物学的进步极大地改变了肿瘤治疗模式,大量科学研究揭示了肿瘤免疫逃逸的机制,各种新型肿瘤免疫治疗应运而生,成为继手术、放疗、化疗、靶向治疗后肿瘤的另一有效治疗手段。本文介绍了肿瘤细胞免疫逃逸的机制,并重点介绍了细胞因子免疫疗法、治疗性单克隆抗体免疫疗法、PD-1/PD-L1疗法、CAR-T疗法、肿瘤疫苗、溶瘤病毒等新型免疫疗法的设计原理、上市生物药物及最新研究进展,同时对比了各免疫疗法的优缺点,为肿瘤免疫治疗中的药物研发提供思路与方法。

     

    Abstract: The progress of molecular biology and tumor biology has greatly changed the mode of cancer treatment. A large number of scientific studies have revealed the mechanism of tumor immune evasion, and a variety of new types of tumor immunotherapy have emerged, which has become another effective treatment of cancer after surgery, radiotherapy, chemotherapy and targeted therapy. This paper introduces the mechanism of tumor cell immune evasion, and focuses on the design principle, biological drugs and the latest research progress of immunotherapy, such as cytokine immunotherapies, therapeutic monoclonal antibody immunotherapy, PD-1/PD-L1 therapy, CAR-T therapy, tumor vaccine, oncolytic virus and so on. At the same time, the advantages and disadvantages of various immunotherapies are compared to provide reference for drug research and development in tumor immunotherapy.

     

/

返回文章
返回